Online citations, reference lists, and bibliographies.
← Back to Search

Genomic Copy Number Alterations In 33 Malignant Peritoneal Mesothelioma Analyzed By Comparative Genomic Hybridization Array.

P. Chirac, D. Maillet, F. Leprêtre, Sylvie Isaac, O. Gléhen, M. Figeac, L. Villeneuve, J. Péron, F. Gibson, F. Galateau-Sallé, François-Noël Gilly, M. Brevet
Published 2016 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant peritoneal mesotheliomas (MPM) are rare, accounting for approximately 8% of cases of mesothelioma in France. We performed comparative genomic hybridization (CGH) on frozen MPM samples using the Agilent Human Genome CGH 180 K array. Samples were taken from a total of 33 French patients, comprising 20 men and 13 women with a mean (range) age of 58.4 (17-76) years. Asbestos exposure was reported in 8 patients (24.2%). Median (range) overall survival (OS) was 39 (0-119) months. CGH analysis demonstrated the presence of chromosomal instability in patients with MPM, with a genomic pattern that was similar to that described for pleural mesothelioma, including the loss of chromosomal regions 3p21, 9p21, and 22q12. In addition, novel genomic copy number alterations were identified, including the 15q26.2 region and the 8p11.22 region. Median OS was associated with a low peritoneal cancer index (P=.011), epithelioid subtype (P=.038), and a low number of genomic aberrations (P=.015), all of which constitute good prognostic factors for MPM. Our results provide new insights into the genetic and genomic background of MPM. Although pleural and peritoneal mesotheliomas have different risk factors, different therapeutics, and different prognosis; these data provide support to combine pleural and peritoneal mesothelioma in same clinical assays.
This paper references
10.1093/ANNONC/MDL345
Epidemiology of peritoneal mesothelioma: a review.
P. Boffetta (2007)
10.1186/s12967-015-0485-1
BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma
H. Alakus (2015)
10.1245/ASO.2006.05.041
Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy: Results of a Prospective Study
C. Brigand (2006)
10.1159/000109618
Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH
P. M. Lindholm (2007)
10.1002/ijc.28502
COUP‐TFII in pancreatic adenocarcinoma: Clinical implication for patient survival and tumor progression
S. Polvani (2014)
10.1245/s10434-015-4644-7
Intraperitoneal Vascular Endothelial Growth Factor: A Prognostic Factor and the Potential for Intraperitoneal Bevacizumab Use in Peritoneal Surface Malignancies
C. Chia (2015)
10.1038/modpathol.2008.45
Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas
S. Chiosea (2008)
10.1002/(SICI)1097-4652(199908)180:2<150::AID-JCP2>3.0.CO;2-H
Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma
S. S. Murthy (1999)
10.1038/ng.912
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
Peritoneal mesothelioma: a review.
A. Bridda (2007)
10.1002/DC.20281
The expression pattern of β‐catenin in mesothelial proliferative lesions and its diagnostic utilities
Yiran Dai (2005)
10.1016/j.ajpath.2010.10.039
Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma.
D. Jean (2011)
10.1111/j.1440-1827.2009.02387.x
Characterization of a complex chromosome aberration in two cases of peritoneal mesothelioma arising primarily in the hernial sac
Gabriella Serio (2009)
10.1038/ng.855
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
Matthew J Bott (2011)
10.1016/j.annpat.2014.01.008
[The RENAPE network: towards a new healthcare organization for the treatment of rare tumors of the peritoneum. Description of the network and role of the pathologists].
L. Villeneuve (2014)
10.1097/MPH.0000000000000262
Malignant Peritoneal Mesothelioma in an Adolescent Male With BAP1 Deletion
Steve Taylor (2015)
10.1007/978-1-4613-1247-5_23
Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis.
P. Jacquet (1996)
10.1007/s12032-014-0071-z
High-resolution genome-wide analysis identified recurrent genetic alterations in NK/T-cell lymphoma, nasal type, which are associated with disease progression
Lin Sun (2014)
10.1111/j.1349-7006.2006.00386.x
Genomic profiling of malignant pleural mesothelioma with array‐based comparative genomic hybridization shows frequent non‐random chromosomal alteration regions including JUN amplification on 1p32
T. Taniguchi (2007)
10.1016/j.cancergen.2012.08.005
Heterozygous loss of NF2 is an early molecular alteration in well-differentiated papillary mesothelioma of the peritoneum.
H. Nemoto (2012)
10.1016/j.annpat.2014.01.009
[The French mesothelioma network from 1998 to 2013].
F. Galateau-Sallé (2014)
10.1517/14712590802666397
Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors.
Q. Chu (2009)
10.1093/nar/gkp1215
Waved aCGH: to smooth or not to smooth
F. Lepretre (2010)
10.1186/1477-3163-7-3
Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors
Shoshana J. Weiner (2008)
10.1093/neuonc/noq158
Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas.
J. Barrow (2011)
10.1073/pnas.1503500112
VEGF-B promotes cancer metastasis through a VEGF-A–independent mechanism and serves as a marker of poor prognosis for cancer patients
Xiaojuan Yang (2015)
Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
P. Illei (2003)
10.1042/BJ3570551
Human cyritestin genes (CYRN1 and CYRN2) are non-functional.
P. Grzmil (2001)
10.1016/j.clcc.2015.02.001
Development of Small Molecules Targeting the Wnt Signaling Pathway in Cancer Stem Cells for the Treatment of Colorectal Cancer.
Lele Song (2015)
10.1093/annonc/mdr477
Importance of gender in diffuse malignant peritoneal mesothelioma.
C. Cao (2012)
10.1016/J.ANNPAT.2014.01.009
Mésothéliome : les dispositifs en place en France « le réseau mésothéliome » 1998–2013
F. Galateau-Sallé (2014)
10.1200/JCO.2012.42.8201
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
E. Van Cutsem (2012)
10.5858/arpa.2012-0214-OA
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.
A. Husain (2013)
10.1038/modpathol.2009.180
Sarcomatoid mesothelioma: a clinical–pathologic correlation of 326 cases
S. Klebe (2010)
10.1517/14712590802666397
Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors
Q. Chu (2009)
10.1186/1477-7800-2-3
Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer
Rhonda L Harmon (2005)
10.1016/j.lungcan.2009.03.018
p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos.
P. Andujar (2010)
10.1158/0008-5472.CAN-14-1008
Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guangwu Guo (2015)
10.1016/J.ANNPAT.2014.01.008
Réseau RENAPE : vers une nouvelle organisation des soins pour le traitement des tumeurs rares du péritoine. Description du réseau et rôle des pathologistes
L. Villeneuve (2014)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1016/S0165-4608(01)00432-0
Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Mesothelioma.
A. Sandberg (2001)
10.1158/0008-5472.CAN-04-0115
Inhibition of Wnt-1 Signaling Induces Apoptosis in β-Catenin-Deficient Mesothelioma Cells
L. You (2004)
10.1002/path.1128
Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases
M. Krismann (2002)
10.1016/J.GDE.2006.12.007
The many ways of Wnt in cancer.
P. Polakis (2007)
10.1016/j.molmed.2015.01.003
Disease implications of the Hippo/YAP pathway.
Steven W Plouffe (2015)
10.1016/j.cancergen.2013.04.006
Integrated high-resolution array CGH and SKY analysis of homozygous deletions and other genomic alterations present in malignant mesothelioma cell lines.
Geula Klorin (2013)



This paper is referenced by
10.1101/243477
Integrated Multi-omics Molecular Subtyping Predicts Therapeutic Vulnerability in Malignant Peritoneal Mesothelioma
Raunak Shrestha (2018)
10.1186/s13073-019-0620-3
BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma
Raunak Shrestha (2019)
10.2147/CMAR.S205723
Analyzing biological and molecular characteristics and genomic damage induced by exposure to asbestos
D. Ospina (2019)
10.1038/s41379-019-0371-0
Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma
S. Brich (2019)
10.3390/cancers12061568
Well-Differentiated Papillary Mesothelioma of the Peritoneum Is Genetically Distinct from Malignant Mesothelioma
Raunak Shrestha (2020)
10.1038/modpathol.2016.188
Genomic Profiling of Malignant Peritoneal Mesothelioma Reveals Recurrent Alterations in Epigenetic Regulatory Genes BAP1, SETD2, and DDX3X
N. Joseph (2017)
Impact d’un réseau national sur la prise en charge des tumeurs rares du péritoine
L. Villeneuve (2017)
10.1016/j.ebiom.2018.12.025
Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma
R. Sciarrillo (2019)
10.1016/j.jtho.2016.12.019
BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas
N. Leblay (2017)
10.1038/s41379-020-0588-y
Molecular characterization of diffuse malignant peritoneal mesothelioma
Y. Hung (2020)
10.17116/onkolog2020904160
Tumors of peritoneum. Treatment algorithms
D. V. Sidorov (2020)
10.1002/cncy.22021
Ancillary studies in pleural, pericardial, and peritoneal effusion cytology
K. Sundling (2018)
10.1101/632810
Well-Differentiated Papillary Mesothelioma of the Peritoneum is Genetically Distinct from Malignant Mesothelioma
Raunak Shrestha (2019)
10.1007/978-3-319-53560-9_10
Cell Signaling and Epigenetic Mechanisms in Mesothelioma
B. Mossman (2017)
10.15167/2421-4248/jpmh2019.60.4.1330
Health impact of exposure to asbestos in polluted area of Southern Italy
L. Vimercati (2019)
10.1016/j.canlet.2019.12.016
Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma.
Béatrice Vanbervliet-Defrance (2019)
10.1016/j.jtho.2017.10.016
Dysregulated Expression of the MicroRNA miR‐137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma
T. G. Johnson (2018)
10.20524/aog.2018.0305
Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives
S. Boussios (2018)
10.1186/s13023-017-0571-y
The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry
L. Villeneuve (2017)
10.1101/243477
BAP1 Haploinsufficiency Predicts a Distinct Immunogenic Class of Malignant Peritoneal Mesothelioma
Raunak Shrestha (2018)
10.14288/1.0370936
Computational prioritization of cancer driver genes for precision oncology
Raunak Shrestha (2018)
10.1101/243477
BAP1 Loss Predicts Therapeutic Vulnerability in Malignant Peritoneal Mesothelioma
Raunak Shrestha (2018)
10.1007/978-981-10-8144-6_12
Pulmonary Malignancies (2): Mesothelioma—What Are the Roles of Genetic Factors in the Pathogenesis of Mesothelioma?
T. Nakano (2018)
10.3390/ht7030020
Genomics and Epigenetics of Malignant Mesothelioma
Adam P Sage (2018)
10.3390/ijms18081818
Peritoneal Mesothelioma with Residential Asbestos Exposure. Report of a Case with Long Survival (Seventeen Years) Analyzed by Cgh-Array
G. Serio (2017)
CMAR_A_205723 4997..5012
Diana Ospina (2019)
10.1007/978-981-10-7053-2_21
Registries and Collaborative Groups in Peritoneal Surface Oncology
A. Bhatt (2018)
10.1016/j.lungcan.2018.11.032
Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.
D. Chapel (2019)
Semantic Scholar Logo Some data provided by SemanticScholar